Mumbai-based global pharma player Lupin Limited has appointed Christine Mundkur as an Independent Director with immediate effect, the company said Monday, recent CEO of Impopharma Inc.
As noted in the announcement, Mundkur most recently served as Chief Executive Officer and Non-voting Chairman of the Board of Directors for Impopharma Inc, a developer of complex formulations focused on inhalation pharmaceutical products, where she led the transition of the company from a successful clinical research organization into a generic pharmaceutical inhalation development company.
She also held leadership positions as President and Chief Executive Officer for North America for Sandoz, Inc. Earlier, she served as Chief Executive Officer of Barr Laboratories, Inc. Ms. Mundkur started her career at Barr as quality and regulatory counsel, Lupin noted in the annoucement.
Vinita Gupta, Chief Executive Officer, Lupin said that Mundkur’s extensive experience in the global pharma industry, significant knowledge in areas like inhalation, biosimilars and proprietary women’s health, and strong experience in operations and quality will be a great asset for Lupin.